Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Prior Placebo

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44399   clinical trials with a EudraCT protocol, of which   7411   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    7,059 result(s) found for: Prior Placebo. Displaying page 23 of 353.
    «« First « Previous 19  20  21  22  23  24  25  26  27  Next» Last»»
    EudraCT Number: 2005-004309-27 Sponsor Protocol Number: P04579 Start Date*: 2005-12-28
    Sponsor Name:Schering Plough Research Institute
    Full Title: Cross-Over Study of the Decongestant Effect of Phenylephrine Compared With Placebo and Pseudoephedrine as Active Control in SAR Subjects Exposed to Pollen in the Vienna Challenge Chamber
    Medical condition: Seasonal Allergic Rhinitis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-001352-13 Sponsor Protocol Number: (ISA05-25) Start Date*: 2006-09-27
    Sponsor Name:Isotechnika Inc
    Full Title: A PHASE III, RANDOMIZED, MULTICENTRE, DOUBLE-BLIND, PLACEBO AND CYCLOSPORINE CONTROLLED STUDY OF ISA247 IN PLAQUE PSORIASIS PATIENTS (ISA05-25)
    Medical condition: Patient has stable, moderate to severe, plaque psoriasis over the previous 6 months; i.e., psoriasis must not be spontaneously improving or worsening in the 4 weeks prior to the screening visit.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003572-38 Sponsor Protocol Number: PSD503-SUI-001 Start Date*: 2005-10-07
    Sponsor Name:Plethora Solutions Limited
    Full Title: A PHASE II, MULTI-CENTRE, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-WAY CROSS-OVER STUDY TO EVALUATE EFFICACY, PLASMA CONCENTRATIONS AND SAFETY OF 0.25ML OF 20%W/W PSD503 FOR TOPICAL APPLICATION IN FEMAL...
    Medical condition: Stress urinary incontinence
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-000388-10 Sponsor Protocol Number: WADA_17C09 Start Date*: 2019-06-11
    Sponsor Name:Daniel Sanabria
    Full Title: Clinical trial on the effects of the tramadol and paracetamol on physical, cognitive and brain performance during cycling
    Medical condition: Sports doping
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-004653-96 Sponsor Protocol Number: PSD502-PM-002 Start Date*: 2006-01-30
    Sponsor Name:Plethora Solutions Limited
    Full Title: Phase II, single centre, randomised, double-blind, placebo-controlled study to determine the efficacy, safety and tolerability of PSD502 in the management of pain in subjects undergoing treatment f...
    Medical condition: Acute minor burns
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-005377-36 Sponsor Protocol Number: D1690C00025 Start Date*: 2015-02-26
    Sponsor Name:AstraZeneca AB, R&D Mölndal
    Full Title: An 8-week, single centre, randomized, parallel-group, double-blind, placebo controlled phase IV study to evaluate Dapagliflozin 10 mg once daily effects on insulin resistance in subjects with type ...
    Medical condition: type 2 diabetes mellitus.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2008-002794-13 Sponsor Protocol Number: ARhiSi-1 Start Date*: 2009-01-28
    Sponsor Name:Bionorica AG
    Full Title: A multi-centre, double-blind, placebo-controlled, randomised, parallel group study to assess the efficacy and safety of two different dosages of a herbal medicinal product (dry extract BNO-1016) in...
    Medical condition: Acute rhinosinusitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052106 Rhinosinusitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001355-12 Sponsor Protocol Number: LPS15198 Start Date*: 2019-02-27
    Sponsor Name:SANOFI-AVENTIS GROUPE
    Full Title: Phase IV, randomized, double-blind, multicenter, placebo-controlled clinical trial to evaluate the efficacy and the safety of enterogermina (Bacillus clausii) in treating patients with small intest...
    Medical condition: Small intestinal bacterial overgrowth (SIBO)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10071061 Small intestinal bacterial overgrowth LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005226-28 Sponsor Protocol Number: D8110C00001 Start Date*: 2021-01-22
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for ...
    Medical condition: SARS-COV-2 infection (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-002999-34 Sponsor Protocol Number: Y-79-52120-126 Start Date*: 2007-12-04
    Sponsor Name:Ipsen Limited
    Full Title: A phase II, international, multi-centre, prospective, randomised, parallel-group, double-blind, dose-ranging, placebo-controlled, 12-week, princeps study to assess the efficacy and safety of a one ...
    Medical condition: Idiopathic overactive bladder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020853 Hypertonic bladder LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) NL (Prematurely Ended) BE (Completed) FR (Completed) CZ (Completed) IT (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-000840-24 Sponsor Protocol Number: CQGE031C2303 Start Date*: 2018-09-04
    Sponsor Name:Novartis Pharma AG
    Full Title: A multi-center, randomized, double-blind, active and placebo-controlled study to investigate the efficacy and safety of ligelizumab (QGE031) in the treatment of Chronic Spontaneous Urticaria (CSU) ...
    Medical condition: Chronic Spontaneous Urticaria
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10072757 Chronic spontaneous urticaria PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) BE (Completed) EE (Completed) ES (Completed) NL (Completed) PT (Not Authorised) SK (Completed) FI (Completed) PL (Completed) GB (GB - no longer in EU/EEA) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2006-005306-31 Sponsor Protocol Number: H6Q-MC-S021 Start Date*: 2007-09-20
    Sponsor Name:Eli Lilly and Company limited
    Full Title: Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Pemetrexed and Cisplatin plus Enzastaurin versus Pemetrexed and Cisplatin plus Placebo in Chemonaive Patients with Advanced, Unresecta...
    Medical condition: advanced, unresectable, or metastatic (stage IIIB or IV) non-small cell lung cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001033-40 Sponsor Protocol Number: VS-6063-202 Start Date*: 2013-07-26
    Sponsor Name:Verastem Inc
    Full Title: A Phase II Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS 6063 in Subjects with Malignant Pleural Mesothelioma
    Medical condition: MPM is a rare but aggressive tumor of the serosal surfaces (specifically the pleura and peritoneum) that is highly invasive and progresses rapidly. The main risk factor is exposure to carcinogeni...
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059518 Pleural mesothelioma malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) BE (Completed) ES (Prematurely Ended) SE (Prematurely Ended) NL (Completed) NO (Completed) PL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001076-11 Sponsor Protocol Number: CTQJ230A12301 Start Date*: 2019-12-19
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients with establishe...
    Medical condition: Cardiovascular Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10051614 Arteriosclerotic cardiovascular disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned) GB (GB - no longer in EU/EEA) DK (Trial now transitioned) SK (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) GR (Trial now transitioned) PT (Trial now transitioned) SE (Trial now transitioned) NL (Ongoing) BG (Trial now transitioned) BE (Trial now transitioned) NO (Trial now transitioned) SI (Trial now transitioned) RO (Trial now transitioned) IS (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-002471-34 Sponsor Protocol Number: AZA-MDS-003 Start Date*: 2012-11-23
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Subjects With Red...
    Medical condition: Subjects with Red Blood Cell Transfusion-Dependent Anemia and Thrombocytopenia due to IPSS Lower-Risk Myelodysplastic Syndromes
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10068361 MDS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NO (Completed) SE (Completed) ES (Ongoing) CZ (Completed) PT (Completed) LT (Completed) IT (Completed) NL (Completed) GB (GB - no longer in EU/EEA) DE (Completed) FI (Completed) DK (Completed) FR (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2020-004986-38 Sponsor Protocol Number: 337HNAS20011 Start Date*: 2022-01-04
    Sponsor Name:Inventiva S.A.
    Full Title: A randomised, double-blind, placebo-controlled, multicentre, Phase 3 study evaluating long-term efficacy and safety of lanifibranor in adult patients with non-cirrhotic non-alcoholic steatohepatiti...
    Medical condition: Non-alcoholic Steatohepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    22.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) AT (Completed) HU (Trial now transitioned) BG (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned) PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-001227-40 Sponsor Protocol Number: SMR-2271(SER100-001) Start Date*: 2013-09-23
    Sponsor Name:Serodus ASA
    Full Title: A randomized, double-blind, placebo-controlled, cross-over, multi-center study assessing the safety, tolerability and efficacy of SER100 10 mg s.c. twice daily for 2 days in patients with Isolated ...
    Medical condition: Isolated Systolic Hypertension
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004866 10050591 Isolated systolic hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) FI (Prematurely Ended) HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-005065-40 Sponsor Protocol Number: TA-8995-302 Start Date*: 2022-05-13
    Sponsor Name:NewAmsterdam Pharma B.V.
    Full Title: Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies (BROADWAY): A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participant...
    Medical condition: dyslipidemia heterozygous familial hypercholesterolemia (HeFH) atherosclerotic cardiovascular disease (ASCVD)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004848 10020049 High cholesterol LLT
    20.0 100000004850 10057079 Heterozygous familial hypercholesterolemia LLT
    26.0 100000004866 10051615 Atherosclerotic cardiovascular disease LLT
    20.0 100000004866 10076622 Atherosclerotic plaque LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DK (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2014-004463-20 Sponsor Protocol Number: 20120297 Start Date*: 2015-10-02
    Sponsor Name:Amgen Inc
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention
    Medical condition: Migraine Prevention
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PT (Completed) GR (Completed) DK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-001247-39 Sponsor Protocol Number: CCR104456 Start Date*: 2005-08-16
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A Phase III, randomised, double-blind, placebo-controlled, multicentre, parallel group study to compare the efficacy and safety of GW873140 400mg BID in combination with a ritonavir-containing opti...
    Medical condition: Treatment of HIV-1 infections
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) IE (Completed) DK (Prematurely Ended) GB (Prematurely Ended) AT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 19  20  21  22  23  24  25  26  27  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 13 04:15:02 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA